SHERIDAN, Wyo., Oct. 13, 2026 /PRNewswire/ --
How big is the sensor patch market, and why is it growing so fast?
The global sensor patch market is valued at USD 7.9 billion in 2026 and is projected to reach USD 28.9 billion by 2031, growing at a CAGR of 29.6% over the forecast period (2026–2031), according to a new study by Wissen Research.
Sensor patches are adhesive, skin-worn devices that continuously or periodically measure signals such as glucose, cardiac activity, and temperature, and transmit the data wirelessly to a smartphone, cloud platform, or clinician. Demand is rising with the global burden of chronic disease, which the World Health Organization links to about 41 million deaths a year, roughly 71% of all deaths worldwide, and with diabetes, which the International Diabetes Federation estimates affected about 589 million adults aged 20–79 in 2024. As care shifts toward remote and home settings, continuous glucose monitoring and ambulatory cardiac monitoring patches are becoming core tools for managing long-term conditions outside the clinic.
Get a Free Sample of This Report to Explore Key Findings and Data: https://www.wissenresearch.com/request-a-sample/?report=sensor-patch-market
From Single-Parameter Patches to Connected, Multimodal Monitoring
The industry is moving away from simple, single-parameter devices toward connected, multimodal sensing systems. Glucose and ECG patches are the commercially mature applications today, while development is focused on temperature, blood pressure, hydration, metabolism, and biochemical sensing. Research platforms increasingly combine electrical, mechanical, thermal, optical, and biochemical sensing on a single flexible electronics substrate, which gives a richer physiological picture than any single device, although many of these systems are still at various stages of validation rather than mass-market maturity.
Biofluid sensing is a second frontier. Wearable microfluidics can collect and analyze sweat, interstitial fluid, saliva, tears, and wound exudate, opening the door to minimally invasive tracking of electrolytes, metabolites, and other biomarkers. Longer-wear glucose products, such as Dexcom's G7 15 Day system and Senseonics' Eversense 365, show the parallel push toward extended wear and fewer sensor replacements, while connectivity with smartphones, cloud platforms, and remote patient monitoring programs turns each patch into a continuous data source for clinicians.
Glucose and Ketones in One Wearable: CGM Reaches a Wider Audience
Glucose monitoring is broadening in two directions. On the clinical side, dual-analyte sensing is arriving: Abbott secured CE Mark approval for Libre Duo, a wearable that continuously tracks both glucose and ketones. On the consumer side, DexCom received FDA clearance to extend its Stelo biosensor to children aged 2 and older who do not use insulin, and announced a redesigned app and planned expansion into the U.K., Australia, New Zealand, and South Korea. Together, these moves show continuous monitoring expanding beyond traditional insulin-dependent users toward wider wellness and prevention use.
What's Fueling Growth in the Sensor Patch Market
- Rising Chronic Disease Burden: Diabetes, heart disease, and chronic lung conditions require frequent measurement, creating demand for continuous monitoring outside traditional clinical settings.
- Growing Diabetes Prevalence: Hundreds of millions of people living with diabetes are expanding the base of potential users for glucose-sensing patches.
- Remote and Home Healthcare: Patches that transmit physiological data to clinicians and digital health platforms reduce reliance on repeated in-clinic measurements and support more mobile patients.
- Advances in Flexible Electronics: Conformable materials, miniaturized low-power components, microfluidics, and wireless communication allow longer, more comfortable wear and more varied measurements.
- Regulatory Acceptance: U.S. FDA records now list multiple cleared continuous glucose monitoring systems from Abbott, Dexcom, and Senseonics, along with ECG patch systems such as iRhythm's Zio, which established a clear regulatory pathway for patch-based monitoring.
- Extended Wear and Wider Access: Longer-wear sensors and consumer-oriented products are lowering replacement frequency and widening the user base.
Challenges Facing the Sensor Patch Market
Maintaining accuracy over long wear periods is the main technical challenge. Signal drift, calibration, biofouling, skin adhesion, battery life, and mechanical deformation all influence performance, and differences in physiology between users can require sophisticated algorithms, calibration routines, and validation. Skin compatibility and comfort matter just as much, since a patch that irritates or detaches will not be worn.
Regulation and data governance add further complexity. Manufacturers must demonstrate safety, efficacy, and software usability for patches that perform monitoring or diagnostic functions, and connected devices must address data security and interoperability across healthcare systems. For newer biochemical and multimodal applications, reaching the mass market will still require clinical validation, scaled-up manufacturing, better calibration, and clearer regulatory frameworks.
Recent Strategic Developments in the Sensor Patch Market
In June 2026, DexCom, Inc. received FDA clearance expanding Stelo to children aged 2 and older who do not use insulin, announced a redesigned Stelo app, and outlined planned expansion into the U.K., Australia, New Zealand, and South Korea.
In May 2026, Abbott Laboratories secured CE Mark approval for Libre Duo and Libre Duo 10 Day, dual glucose-ketone wearables offering up to 15 or 10 days of wear and integrating with Abbott's Libre digital health ecosystem, with European launches planned later in 2026.
In April 2026, iRhythm Technologies, Inc. agreed to acquire VitalConnect, Inc. for approximately USD 287.5 million, combining its Zio cardiac monitoring service with VitalConnect's VitalPatch biosensor, which uses AI-enabled algorithms to deliver real-time ECG and vital-sign data through cloud connectivity, and expanding iRhythm's hospital and remote-care reach.
Taken together, these moves show consolidation among cardiac monitoring providers, wider access to glucose monitoring, and growing interest in multi-analyte sensing.
Key Insights from Sensor Patch Market Analysis
- Amperometric technology held the largest share by technology type in 2025, supported by the scale of continuous glucose monitoring. Abbott reports about 7 million FreeStyle Libre users worldwide and USD 6.8 billion in 2024 diabetes care revenue, while DexCom reported USD 4.662 billion in 2025 revenue, up 16% from 2024, and about 3.5 million customers at year-end 2025.
- Bodywear held the largest share by wearable type in 2025, driven by sensors worn on the upper arm and torso. iRhythm reported USD 747.1 million in 2025 revenue, up 26.2%, on growing Zio volume, reinforcing demand for body-worn cardiac patches.
- North America held the largest regional share in 2025, supported by developed healthcare infrastructure, strong adoption of digital health, a favorable regulatory framework, and the presence of leading glucose and cardiac monitoring companies.
- Asia Pacific is the fastest-growing region, with the report covering China, Japan, India, Australia and New Zealand, and South Korea.
- The market is moderately consolidated in established applications such as continuous glucose monitoring and ambulatory cardiac monitoring, but fragmented across emerging sensing technologies, where competition turns on accuracy, clinical validation, wear duration, connectivity, and manufacturing scale.
Key Players in the Sensor Patch Market
Leading companies in the sensor patch market are focused on continuous glucose monitoring, ambulatory cardiac monitoring, physiological sensing, flexible electronics, sensor miniaturization, wireless connectivity, and data analytics.
Regional Analysis and Growth Opportunities
North America leads the an established U.S. regulatory framework, supported by highly developed healthcare infrastructure, wide acceptance of digital health technology, a strong investment climate, and a concentration of leading continuous glucose monitoring and cardiac monitoring companies. The U.S. regulatory framework for sensor-based digital health technologies has produced a long record of FDA-cleared glucose monitors, cardiac monitors, and remote monitoring devices, and the country is a pioneer in flexible biosensors, connected medical devices, and digital clinical trials.
Asia Pacific is the fastest-growing region. Commercial interest is already visible in planned launches such as DexCom's expansion of Stelo into Australia, New Zealand, and South Korea, and the report profiles regional demand across China, Japan, India, Australia and New Zealand, and South Korea.
Europe, Latin America, and the Middle East & Africa complete the report's regional coverage, with Abbott's CE Mark for Libre Duo illustrating regulatory progress in Europe.
Get a Custom Briefing on This Market for Your Business
Wissen Research's healthcare technology analysts are available to walk through findings specific to your market, region, or competitive set.
Need Insights Specific to Your Business? Request a Customized Version of This Report: https://www.wissenresearch.com/request-customization/?
